Although hundreds of Oxbryta fatalities were reported through the FDA's adverse event reporting system, lawsuits point out that it took Pfiizer years to issue an Oxbryta recall.
Days after the FDA announced a BioZorb recall, an Arkansas woman has filed a lawsuit, indicating that her BioZorb tissue marker migrated out of position, causing pain and disfigurement, instead of harmlessly absorbing into the body as advertised.
The FDA is requiring new label warnings for Ozempic, Wegovy, Mounjaro and all other GLP-1 drugs, indicating they may cause pulmonary aspiration during surgery.
